^
    2d
    Treatment Strategies in Metastatic Castration-Resistant Prostate Cancer: A Narrative Review of Considerations in the Post-ARTA, Post-Docetaxel Setting. (PubMed, Oncol Ther)
    Available therapeutic options include radioligand therapy (e.g. lutetium-177-PSMA-617), cabazitaxel, PARP inhibitors (particularly for patients with DNA repair gene alterations), second-line ARTAs, further chemotherapy and immunotherapeutic approaches. Finally, the review provides an overview of promising emerging therapies poised to expand the treatment landscape for mCRPC. These include bispecific T cell engagers, androgen receptor degraders, and antibody-drug conjugates, which are currently under investigation in clinical trials and may soon offer new avenues for treatment beyond traditional mechanisms.
    Review • Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
    |
    AR (Androgen receptor) • BRCA (Breast cancer early onset) • FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    6d
    PSMAndARPI: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=420 --> 7
    Enrollment closed • Enrollment change
    |
    Xtandi (enzalutamide) • abiraterone acetate • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    7d
    Current and future perspectives on radioligand therapy in advanced prostate cancer. (PubMed, Ther Adv Med Oncol)
    Nonetheless, challenges remain around long-term hematologic and renal safety, radionuclide supply, protocol standardization, and global accessibility. Ongoing and future multicenter trials, collaborative consortia, and innovations in theranostics will be critical to defining optimal patient selection, sequencing with existing therapies, and embedding RLT as a key pillar in the management of advanced PCa.
    Review • Journal
    |
    STEAP1 (STEAP Family Member 1) • KLK2 (Kallikrein-related peptidase 2)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    13d
    A single arm study of Androgen Receptor Pathway inhibition plus Adaptive-dosed [177Lu]Lu-PSMA-597 in metastatic hormone sensitive prostate cancer (OPTIMAL-e). (ACTRN12626000034336)
    P2, N=20, Not yet recruiting, St Vincent's Health Network
    New P2 trial
    |
    FOLH1 positive
    14d
    A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer (clinicaltrials.gov)
    P1/2, N=55, Recruiting, Yunhe Pharmaceutical (Tianjin) Co., Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    21d
    A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=370, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P3 trial
    |
    Xtandi (enzalutamide) • abiraterone acetate
    21d
    AcTFirst: Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (clinicaltrials.gov)
    P3, N=940, Recruiting, Novartis Pharmaceuticals | Trial primary completion date: Sep 2028 --> Feb 2028
    Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • 225Ac-vipivotide tetraxetan (AAA817)
    23d
    NeoPSMA: Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Novartis Pharmaceuticals | N=228 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    177Lu-PSMA-R2
    1m
    ACCEL: [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=142, Active, not recruiting, Eli Lilly and Company | Recruiting --> Active, not recruiting
    Enrollment closed
    1m
    Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (clinicaltrials.gov)
    P1/2, N=29, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=70 --> 29
    Enrollment closed • Enrollment change
    |
    FOLH1 positive
    1m
    177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, University of California, San Francisco | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan)
    1m
    PSMA-PRED: Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Centre Jean Perrin | Trial completion date: Dec 2028 --> Jun 2034 | Trial primary completion date: Dec 2026 --> Jun 2034
    Trial completion date • Trial primary completion date
    |
    lutetium zadavotide guraxetan (PNT2002)